Globus Medical, Inc. (GMED)

Globus Medical, Inc. (GMED) is a healthcare company (medical devices) based in the United States. The share price is $70.37, down 0.18% on the day, which values the company at $9.32B. Price as of 17 Nov 2026, 17:40 UTC, from Yahoo Finance.

Key facts

Share price
$70.37−0.18% today
Market value
$9.32B
P/E ratio
17.3×last 12 months
Forward P/E
13.2×
Funk Score
85/100
Against its own history
Well below its usual priceusual price $129.95
200-week average
$68.473% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Globus Medical, Inc. in more detail

GMED trades at 17.3× its last twelve months' earnings, 13.2× next year's expected earnings, 3.0× sales. Measured against its own history, the price is 46% below what its usual multiples would imply ($129.95) — well below its usual price. It sits 3% above its 200-week average of $68.47.

Over the last five fiscal years Globus Medical, Inc. has compounded revenue 30.1% a year, earnings per share 31.2% a year, free cash flow 33.8% a year. Its Funk Score is 85 out of 100 (financial strength 10.0, profitability 6.9, growth 10.0, value 7.0, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

3 of the superinvestors tracked here hold GMED, including Ray Dalio (founder) (0.1% of the portfolio), Sequoia Fund team (0.1% of the portfolio), Jeremy Grantham (co-founder) (0.1% of the portfolio).

Superinvestors holding GMED

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:GMED vs BRKR (Globus Medical, Inc. vs Bruker)GMED vs MDGL (Globus Medical, Inc. vs Madrigal Pharmaceuticals)GMED vs PODD (Globus Medical, Inc. vs Insulet)GMED vs QGEN (Globus Medical, Inc. vs Qiagen)GMED vs SYRE (Globus Medical, Inc. vs Spyre Therapeutics)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Globus Medical, Inc. (GMED): questions and answers

What is GMED's P/E ratio?

Globus Medical, Inc. trades at 17.3× its last twelve months' earnings and 13.2× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 13.1× to 110.3×, with a median of 32.7×.

What is GMED's PEG ratio?

Globus Medical, Inc.'s PEG ratio is 2.76 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Globus Medical, Inc.'s market cap?

Globus Medical, Inc. is valued at $9.32B at a share price of $70.37.

Is GMED overvalued or undervalued?

Against its own history, GMED is well below its usual price: the price is 46% below the $129.95 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is GMED above its 200-week moving average?

Yes. GMED is 2.8% above its 200-week average of $68.47. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Globus Medical, Inc. growing?

Over the last five fiscal years Globus Medical, Inc.'s revenue grew 30.1% a year and its earnings per share 31.2% a year; over ten years revenue grew 18.4% a year.

Cite this page

Funkfolio, “Globus Medical, Inc. (GMED) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/GMED

Underlying data: Yahoo Finance; company filings with the SEC.